Paolo Colombo, Pharm. D., Ph.D.

AIMBE College of Fellows Class of 2020
For seminal contributions to novel drugs/proteins for treatment of angina pectoris, serotonin control uptake inhibitors, Parkinson and benign prostatic heperplasia.

Go behind the virus on its entry way with targeted pharmacological therapy: the inhalation route of anti SARS-Cov2 active substances.

Via AIMBE Public Documents | May 21, 2020


SARS-Cov2 is the last appeared coronavirus that developed a pandemic infection with huge number of fatal cases. No vaccines are yet available that protect from this infection. However, a number of therapeutic tactics against COVID-19 have been empirically started.

According to Mehra et al., 2020, in COVID-19 illness, a structured approach to clinical is imperative (1). Such approach distinguish the phase in which the viral pathogenicity is dominant, from the phase where the host inflammatory response overtakes the pathology. Therefore, after five months of epidemy, 3-stage’s progression of illness, corresponding to increasing severity with distinct clinical signs, therapy responses and clinical outcomes, has been assessed. These stages constitute the reference for investigation and proposition of effective targeted therapies (1).

Stage I is the phase where the early infection causes to most people mild or asymptomatic disease. Treatment at this level with drug having antiviral activity could prevent the progression to severe disease. Stage II (moderate) corresponds to the pulmonary involvement without (IIa) and with (IIb) hypoxia. In this stage the pulmonary disease is established with viral lung multiplication and localized inflammation. The patients develop a viral pneumonia, with cough, fever and possibly hypoxia. Now, not only antiviral drugs are required but, in particular, the inflammation has to be considered and treated. Stage III is the phase in which an extra-pulmonary systemic hyperinflammation syndrome manifests. Likely, a minority of Covid-19 patients transit to this stage where the therapy is essentially against the so called “inflammation storm… Continue reading.


Dr. Paolo Colombo Inducted into AIMBE College of Fellows

Via AIMBE | March 30, 2020

WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Paolo Colombo, Pharm. D., Ph.D., CEO of PlumeStars, Emeritus Professor, Department of Food and Drug, University of Parma, Italy, to its College of Fellows.

Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.”

Dr. Colombo was nominated, reviewed, and elected by peers and members of the College of Fellows for “seminal contributions to novel drugs/proteins for treatment of angina pectoris, serotonin control uptake inhibitors, Parkinson and benign prostatic heperplasia.